Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (trading symbol: AGE) on August 22, 2023. The registrant is a Delaware corporation headquartered in Alameda, California, and is classified as an emerging growth company. The report details a specific financial event occurring on the date of the report.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data for a reporting period. The specific financial metric disclosed is a new debt obligation:
- Debt Drawdown: $500,000 drawn from an existing credit facility.
- Instrument: Amended and Restated Secured Convertible Promissory Note with Juvenescence Limited.
- Repayment Date: February 14, 2024.
Material Changes
The material change reported is the creation of a direct financial obligation. On August 22, 2023, the company utilized $500,000 of available credit under its Secured Note. This increases the outstanding principal balance due to the lender. The filing references prior 8-K filings (June 8, 2023, and August 4, 2023) and a 10-Q (May 12, 2023) for the full terms of the note, but does not detail changes in other financial metrics versus prior periods.
Guidance, Outlook, and Risks
The filing contains standard forward-looking statement disclaimers, noting that actual results may differ materially from anticipated results due to various risk factors detailed in the company's periodic SEC reports. No specific operational guidance, revenue outlook, or management commentary regarding future performance is provided in this document. The primary contingency noted is the repayment obligation of the drawn principal on February 14, 2024.
Investor Verification Checklist
- Verify the total outstanding principal balance of the Secured Note with Juvenescence Limited following this $500,000 draw.
- Review the full terms of the Amended and Restated Secured Convertible Promissory Note as referenced in the May 12, 2023, 10-Q and prior 8-K filings.
- Confirm the company's current liquidity position to assess its ability to repay the $500,000 by the February 14, 2024, maturity date.
- Check for any subsequent filings regarding further draws or amendments to the credit facility.